HomeCompareALBO vs STAG

ALBO vs STAG: Dividend Comparison 2026

ALBO yields 4.53% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALBO wins by $8.6K in total portfolio value
10 years
ALBO
ALBO
● Live price
4.53%
Share price
$44.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.9K
Annual income
$605.56
Full ALBO calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.09
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.22
Full STAG calculator →

Portfolio growth — ALBO vs STAG

📍 ALBO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALBOSTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALBO + STAG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALBO pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALBO
Annual income on $10K today (after 15% tax)
$385.05/yr
After 10yr DRIP, annual income (after tax)
$514.73/yr
STAG
Annual income on $10K today (after 15% tax)
$292.45/yr
After 10yr DRIP, annual income (after tax)
$392.89/yr
At 15% tax rate, ALBO beats the other by $121.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALBO + STAG for your $10,000?

ALBO: 50%STAG: 50%
100% STAG50/50100% ALBO
Portfolio after 10yr
$22.6K
Annual income
$533.89/yr
Blended yield
2.36%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ALBO right now

ALBO
Analyst Ratings
7
Buy
5
Hold
Consensus: Buy
Price Target
$44.00
-0.3% upside vs current
Range: $42.00 — $48.00
Altman Z
0.5
Piotroski
4/9
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.7% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALBO buys
0
STAG buys
0
No recent congressional trades found for ALBO or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALBOSTAG
Forward yield4.53%3.44%
Annual dividend / share$2.00$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0.3%
Portfolio after 10y$26.9K$18.3K
Annual income after 10y$605.56$462.22
Total dividends collected$5.3K$4.0K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$44.00$45.00

Year-by-year: ALBO vs STAG ($10,000, DRIP)

YearALBO PortfolioALBO Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$11,153$453.00$10,665$345.09+$488.00ALBO
2$12,406$472.18$11,364$357.70+$1.0KALBO
3$13,765$490.86$12,098$370.43+$1.7KALBO
4$15,238$509.01$12,869$383.28+$2.4KALBO
5$16,831$526.60$13,677$396.23+$3.2KALBO
6$18,553$543.61$14,524$409.27+$4.0KALBO
7$20,411$560.02$15,411$422.41+$5.0KALBO
8$22,416$575.82$16,339$435.61+$6.1KALBO
9$24,576$591.00$17,311$448.89+$7.3KALBO
10$26,902$605.56$18,327$462.22+$8.6KALBO

ALBO vs STAG: Complete Analysis 2026

ALBOStock

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Full ALBO Calculator →

STAGREIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this ALBO vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALBO vs SCHDALBO vs JEPIALBO vs OALBO vs KOALBO vs MAINALBO vs PLDALBO vs EQRALBO vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.